Citations

Clear

19 citation(s) found for "Kim, Grace".

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Pl
Khanna, Dinesh , Spino, Cathie , Kleerup, Eric C., Harui, Airi, Ibrahim, Grace, Kim, Grace Hyun J. , Huang, Suiyuan, McLain, Richard, Tu, Yi‐Hsuan, Steen, Virginia , Weigt, S. Samuel , Lee, Joyce , Fischer, Aryeh , Scholand, Mary Beth , Gordon, Jessica , Dellaripa, Paul F. , Rosas, Iván O. , Hunninghake, Gary M. , Trojanowski, Marcin A. , Dematte, Jane E. , Hsu, Vivien , Domsic, Robyn T. , Raghu, Ganesh , Boente, R. , Roth, Michael D. , Investigators, the Scleroderma Lung Study III, Kim, Grace Hyun J , Nagaraja, Vivek , Silver, Richard M. , Gordon, Jessica K , Dellaripa, Paul F , Domsic, Robyn T , Mayes, Maureen D , Boente, Ryan D , Roth, Michael D , Khanna, Dinesh , Lee, Joyce S , Hunninghake, Gary M , Tashkin, Donald P. , Bernstein, Elana J. , Goldin, Jonathan , Nagaraja, Vivek , Simms, Robert W. , Mayes, Maureen D. , Investigators, the Scleroderma Lung Study III

Mayo Clinic

ACR Open Rheumatology | November 26, 2025 | Volume: 7 | Issue: 12 | Pages: No page available

10.1002/acr2.70126 | PMID 41294296 Get It

Objective Mycophenolate mofetil (MMF) can stabilize or improve lung function in systemic sclerosis–related interstitial lung disease (SSc‐ILD). We hypothesized that combining MMF with pirfenidone (PFD) would produce a significantly more rapid and/or greater improvement in lung function. Methods A randomized (1:1), double‐blind, placebo (PLA)‐controlled phase 2 trial was conducted in SSc‐ILD in which patients received PFD or PLA (801 mg three times daily) along with MMF (1,500 mg twice daily) for 18 months. The primary outcome was change in percent predicted forced vital capacity (FVC‐%). Linear mixed‐effects models assessed treatment differences in a modified intention‐to‐treat population. Results Only fifty‐one of 150 intended subjects (34%) were randomized (MMF+PLA, n = 24; MMF+PFD, n = 27). The FVC‐% improved from baseline to 18 months by 2.24 ± 1.35 (least‐squares mean [LSM] ± SEM) in the MMF+PLA group and 2.09 ± 1.28 in the MMF+PFD group (LSM treatment difference −0.14; P = 0.93). Median time to achieve a ≥3% improvement in FVC‐% was numerically faster in the MMF+PFD versus MMF+PLA group (12.3 vs 17.8 months, respectively), but the difference was not significant ( P = 0.33). For secondary outcomes, only the change over 18 months in the Patient‐Reported Outcomes Measurement Information System 29‐item physical function score, favoring MMF+PFD, reached statistical significance ( P = 0.04). Although other related patient‐reported outcomes (PROs) numerically favored the MMF+PFD group, as did quantitative high‐resolution computed tomography measures of ILD, the differences between groups did not reach statistical significance. Early withdrawals from study medication and adverse events of special interest were numerically greater with MMF+PFD (n = 8 vs 2 and n = 20 vs 7, respectively). Conclusion In this underpowered study, there was no statistically significant treatment difference in overall change in FVC‐% between groups. MMF+PFD was not as well tolerated as MMF+PLA.
Orofacial Granulomatosis and Crohn's Disease: A Case Series
Urquhart, Siri A. , Kim, Grace Y. , Anderson, Katelyn , Anderson, Katelyn R, Chedid, Victor G , Chedid, Victor

Mayo Clinic

ACG Case Reports Journal | November 16, 2024 | Volume: 11 | Issue: 11 | Pages: e01559

10.14309/crj.0000000000001559 | PMID 39559789 Get It

ABSTRACT Orofacial granulomatosis (OFG) is a rare syndrome that can occur in association with Crohn's disease (CD). The electronic medical record was searched for “OFG” and “CD.” A total of 297 patients were identified, and relevant data were abstracted. Five patients met inclusion criteria. Most (80%) had ileocolonic CD with nonstricturing/nonpenetrating phenotype. The most common treatments included intralesional corticosteroids (4 patients), oral corticosteroids (3 patients), and anti-TNF agents, specifically infliximab (3 patients). Intralesional corticosteroid administration was followed by partial response in 3 patients, but recurrences were common following initial injection. One patient had no response to topical or oral corticosteroids, antihistamines, or oral antibiotics, but partial response to intralesional corticosteroids and infliximab. None of the patients had complete response to any therapies directed at this condition. OFG may be characterized by partial response, often requiring long-term therapy. Additional investigations into novel treatments may improve future clinical outcomes.
Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population
Reddy, K. Rajender , Izzy, Manhal , Frederick, R. Todd , Rubin, Raymond A. , Fricker, Zachary , Ikahihifo-Bender, Jade , Harte, Maggie , Garcia, Sandra, Campbell, Kathryn, Olofson, Amy , Razavi, Ryan F., James, Janelle M., Patel, Het , Kim-Lee, Grace, Witkiewicz, Sherry , Tobin, William, Jamil, Khurram , Weinberg, Ethan M , Gonzalez, Stevan A , Izzy, M , Simonetto, Douglas A , Frederick, R Todd , Rubin, Raymond A , Ikahihifo-Bender, Jade , Olofson, Amy , Kim-Lee, Grace , Witkiewicz, Sherry , Jamil, Khurram , Weinberg, Ethan M. , Simonetto, Douglas A.

Mayo Clinic

Liver Transplantation | May 21, 2024 | Volume: 30 | Issue: 10 | Pages: 1026-1038

10.1097/lvt.0000000000000399 | PMID 38771635 Get It

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model for End-Stage Liver Disease (MELD) ≥35 were exclusions. Fifty hospitalized patients who received midodrine and octreotide or norepinephrine for HRS-AKI served as a historical comparator cohort. Complete response (CR) was defined as a ≥30% decrease in SCr with end-of-treatment (EOT) SCr≤1.5, partial response as a ≥30% decrease in SCr with EOT SCr>1.5, and nonresponse as a <30% decrease in SCr. CR rate was significantly higher in the terlipressin cohort compared to the historical cohort (64% vs. 16%, p<0.001). Survival, while numerically higher in those who received terlipressin, was statistically similar (D30: 94% vs. 82%, p=0.12; D90: 78% vs. 68%, p=0.37). Renal replacement therapy (RRT) was more common among terlipressin NR than CR and PR (70% vs. 3% vs. 13%, p < 0.001). EOT MELD and SCr were significantly lower within terlipressin cohort (MELD: 19 vs. 25, SCr: 1.4 vs. 2.1 mg/dL, p<0.001). Sixteen of 40 terlipressin-treated patients received LT-alone (terlipressin CR in 10/16). One patient on terlipressin had a hypoxic respiratory failure that responded to diuretics; one possibly had drug-related rash. With continuous terlipressin infusion, a CR rate of 64% was observed with a favorable safety profile. Terlipressin use was associated with lower EOT MELD and SCr than the historical midodrine and octreotide/norepinephrine cohort; LT-alone was accomplished in a high proportion of complete terlipressin responders.
AAPM WGPE report 394: Simulated error training for the physics plan and chart review
Johnson, Perry , Schubert, Leah , Kim, Grace Gwe‐Ya, Faught, Jacqueline, Buckey, C, Luk, Samuel M. H. , Parker, S. , Conroy, Leigh , Schofield, Deborah

Mayo Clinic

Medical Physics | April 8, 2024 | Volume: 51 | Issue: 5 | Pages: 3165-3172

10.1002/mp.17051 | PMID 38588484 Get It

AbstractBackgroundSimulated error training is a method to practice error detection in situations where the occurrence of error is low. Such is the case for the physics plan and chart review where a physicist may check several plans before encountering a significant problem. By simulating potentially hazardous errors, physicists can become familiar with how they manifest and learn from mistakes made during a simulated plan review.PurposeThe purpose of this project was to develop a series of training datasets that allows medical physicists and trainees to practice plan and chart reviews in a way that is familiar and accessible, and to provide exposure to the various failure modes (FMs) encountered in clinical scenarios.MethodsA series of training datasets have been developed that include a variety of embedded errors based on the risk‐assessment performed by American Association of Physicists in Medicine (AAPM) Task Group 275 for the physics plan and chart review. The training datasets comprise documentation, screen shots, and digital content derived from common treatment planning and radiation oncology information systems and are available via the Cloud‐based platform ProKnow.ResultsOverall, 20 datasets have been created incorporating various software systems (Mosaiq, ARIA, Eclipse, RayStation, Pinnacle) and delivery techniques. A total of 110 errors representing 50 different FMs were embedded with the 20 datasets. The project was piloted at the 2021 AAPM Annual Meeting in a workshop where participants had the opportunity to review cases and answer survey questions related to errors they detected and their perception of the project's efficacy. In general, attendees detected higher‐priority FMs at a higher rate, though no correlation was found between detection rate and the detectability of the FMs. Familiarity with a given system appeared to play a role in detecting errors, specifically when related to missing information at different locations within a given software system. Overall, 96% of respondents either agreed or strongly agreed that the ProKnow portal and training datasets were effective as a training tool, and 75% of respondents agreed or strongly agreed that they planned to use the tool at their local institution.ConclusionsThe datasets and digital platform provide a standardized and accessible tool for training, performance assessment, and continuing education regarding the physics plan and chart review. Work is ongoing to expand the project to include more modalities, radiation oncology treatment planning and information systems, and FMs based on emerging techniques such as auto‐contouring and auto‐planning.
S8 Orofacial Granulomatosis and Crohn’s Disease: A Case Series
Kim, Grace Y. , Anderson, Katelyn , Chedid, Victor , Chedid, Victor G , Urquhart, Siri A.

Mayo Clinic

American Journal of Gastroenterology | December 14, 2023 | Volume: 118 | Issue: 12S | Pages: S3-S3

10.14309/01.ajg.0000995768.54192.ed Get It

The effect of exercise post vertebral augmentation in osteoporotic patients: A systematic review and meta‐analysis
Than, Christian A. , Adra, Maamoun , Curtis, Tom J., Shi, Ao , Nakanishi, Hayato , Brown, Johnathan M, Dannawi, Zaher, Beck, Belinda R. , Matar, Reem H, Than, Christian A , Than, Christian A , Kim, Grace , Matar, Reem

Mayo Clinic

Journal of Orthopaedic Research | May 19, 2023 | Volume: 41 | Issue: 12 | Pages: 2703-2712

10.1002/jor.25631 | PMID 37203781 Get It

AbstractThis meta‐analysis investigated the effects of exercise on Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) scores following vertebroplasty or kyphoplasty in osteoporotic fractures. A literature search of PubMed, EMBASE (Elsevier), CiNAHL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, and Web of Science was conducted from database inception to October 6, 2022. Eligible studies reported osteoporosis patients over 18 years of age with a diagnosis of at least one vertebral fracture via radiography or clinical assessment. This review was registered in PROSPERO (ID: CRD42022340791). Ten studies met the eligibility criteria (n = 889). VAS scores at baseline were 7.75 (95% CI: 7.54, 7.97, I2 = 76.11%). Following initiation of exercise, VAS scores at the endpoint of 12 months were 1.91 (95% CI: 1.53, 2.29, I2 = 92.69%). ODI scores at baseline were 68.66 (95% CI: 56.19, 81.13, I2 = 85%). Following initiation of exercise, ODI scores at the endpoint of 12 months were 21.20 (95% CI: 14.52, 27.87, I2 = 99.30). A two‐arm analysis demonstrated improved VAS and ODI for the exercise group compared to non‐exercise control at 6 months (MD = −0.70, 95% CI: −1.08, −0.32, I2 = 87% and MD = −6.48, 95% CI: −7.52, −5.44, I2 = 46%, respectively) and 12 months (MD = −0.88, 95% CI: −1.27, −0.49, I2 = 85% and MD = −9.62, 95% CI: −13.24, −5.99, I2 = 93%). Refracture was the only adverse event reported and occurred almost twice as frequently in the non‐exercise group than in the exercise group. Exercise rehabilitation post vertebral augmentation is associated with improved pain and functionality, particularly after 6 months of exposure, and may reduce refracture rate.
Medical physics practice guideline 4.b: Development, implementation, use and maintenance of safety checklists
Conroy, Leigh , Faught, Jacqueline, Bowers, Erika, Ecclestone, Gillian, Santos, Luis E. Fong de los, Hsu, Annie , Johnson, Jennifer Lynn, Kim, Grace Gwe‐Ya, Schechter, Naomi R., Schubert, Leah , Sterling, David A. , Fong de Los Santos, Luis E, Sterling, David A.

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 5, 2023 | Volume: 24 | Issue: 3 | Pages: No page available

10.1002/acm2.13895 | PMID 36739483 Get It

AbstractThe American Association of Physicists in Medicine (AAPM) is a nonprofit professional society whose primary purposes are to advance the science, education, and professional practice of medical physics. The AAPM has more than 8000 members and is the principal organization of medical physicists in the US. The AAPM will periodically define new practice guidelines for medical physics practice to help advance the science of medical physics and to improve the quality of service to patients throughout the US. Existing medical physics practice guidelines will be reviewed for the purpose of revision or renewal, as appropriate, on their fifth anniversary or sooner. Each medical physics practice guideline represents a policy statement by the AAPM, has undergone a thorough consensus process in which it has been subjected to extensive review, and requires the approval of the Professional Council. The medical physics practice guidelines recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guidelines and technical standards by those entities not providing these services is not authorized. The following terms are used in the AAPM practice guidelines: Must and must not: Used to indicate that adherence to the recommendation is considered necessary to conform to this practice guideline. While must is the term to be used in the guidelines, if an entity that adopts the guideline has shall as the preferred term, the AAPM considers that must and shall have the same meaning. Should and should not: Used to indicate a prudent practice to which exceptions may occasionally be made in appropriate circumstances.
Diagnostic quality model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML
Lennerz, Jochen K. , Salgado, Roberto, Thierauf, Julia , Indave, Iciar, Bard, Adam Z. , Heher, Yael , Baca, Monica E. de , Cree, Ian A. , Bennett, Shannon M. , Özben, Tomris , Ritterhouse, Lauren L. , Bennett, Shannon, Lennerz, Jochen , Salgado, Roberto , Kim, Grace , Sirintrapun, Sahussapont Joseph , Singh, Ankit Kumar , Weissinger, Stephanie Ellen , Bennett, Shannon, Carobene, Anna

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | January 25, 2023 | Volume: 61 | Issue: 4 | Pages: 544-557

10.1515/cclm-2022-1151 | PMID 36696602 Get It

Abstract Background Laboratory medicine has reached the era where promises of artificial intelligence and machine learning (AI/ML) seem palpable. Currently, the primary responsibility for risk-benefit assessment in clinical practice resides with the medical director. Unfortunately, there is no tool or concept that enables diagnostic quality assessment for the various potential AI/ML applications. Specifically, we noted that an operational definition of laboratory diagnostic quality – for the specific purpose of assessing AI/ML improvements – is currently missing. Methods A session at the 3rd Strategic Conference of the European Federation of Laboratory Medicine in 2022 on “ AI in the Laboratory of the Future” prompted an expert roundtable discussion. Here we present a conceptual diagnostic quality framework for the specific purpose of assessing AI/ML implementations. Results The presented framework is termed diagnostic quality model (DQM) and distinguishes AI/ML improvements at the test, procedure, laboratory, or healthcare ecosystem level. The operational definition illustrates the nested relationship among these levels. The model can help to define relevant objectives for implementation and how levels come together to form coherent diagnostics. The affected levels are referred to as scope and we provide a rubric to quantify AI/ML improvements while complying with existing, mandated regulatory standards. We present 4 relevant clinical scenarios including multi-modal diagnostics and compare the model to existing quality management systems. Conclusions A diagnostic quality model is essential to navigate the complexities of clinical AI/ML implementations. The presented diagnostic quality framework can help to specify and communicate the key implications of AI/ML solutions in laboratory diagnostics.
Local Recurrence Rates of Extramammary Paget Disease Are Lower After Mohs Micrographic Surgery Compared With Wide Local Excision: A Systematic Review and Meta-Analysis
Kim, Grace Y. , Campbell, Elliott H. , Brewer, Jerry D.

Mayo Clinic

Dermatologic Surgery | October 7, 2022 | Volume: 49 | Issue: 1 | Pages: 8-12

10.1097/dss.0000000000003601 | PMID 36206405 Get It

BACKGROUND Extramammary Paget disease (EMPD) is a rare, slow growing neoplasm that presents most commonly in the anogenital region of older adults. OBJECTIVE To analyze the difference in local recurrence rates of EMPD in patients treated with wide local excision (WLE) versus Mohs micrographic surgery (MMS). MATERIALS AND METHODS A systematic review of the literature and meta-analysis were performed. Inclusion criteria were adults greater than 18 years of age with a diagnosis of EMPD who have undergone surgical intervention and had follow-up data. Studies were independently reviewed by 2 coinvestigators with discrepancies resolved by the principal investigator. RESULTS Twenty-seven studies met the inclusion criteria. Patients had a 2.67 times higher chance of local recurrence after WLE than MMS (95% confidence interval [CI]:1.47, 4.85; p = .001). Meta-analysis of single-arm studies revealed a 7.3% local recurrence rate after MMS (95% CI: 0.039, 0.107; p < .001) versus a 26.3% recurrence rate after WLE (95% CI: 0.149, 0.376; p < .001). After excluding recurrent tumors, the odds ratio for recurrence in WLE versus MMS was 2.3 (95% CI: 0.285, 18.43, p = .435). CONCLUSION There is a clinically and statistically increased risk of local recurrence of EMPD after WLE compared with MMS.
Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma
Hosseini, Mojgan , Allende, Daniela , Esposito, Iréne , Shi, Jiaqi , Dhall, Deepti, Graham, Rondell P. , Baştürk, Olca , Hruban, Ralph H. , Klimstra, David S. , Adsay, Volkan , Society, for the Pancreatobiliary Pathology, Graham, Rondell P , Adsay, N Volkan , Wang, Huamin , Chetty, Runjan , Matsuda, Yoko , Deshpande, Vikram , Jang, Kee‐Taek , Kim, Grace , Luchini, Claudio , Reid, Michelle D. , Krasinskas, Alyssa M. , Society, for the Pancreatobiliary Pathology

Mayo Clinic

American Journal of Surgical Pathology | December 10, 2021 | Volume: 46 | Issue: 6 | Pages: 754-764

10.1097/pas.0000000000001853 | PMID 34889852 Get It

Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.